The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis

Authors:

Abstract
Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A5 and has a narrow therapeutic range with large inter-individual variability. CYP3A5*3 polymorphism is reported to be functional and may contribute to the inter-individual variability. The objective of this meta-analysis was to accurately estimate the effect of CYP3A5*3 allele on CsA dose-adjusted blood concentration. A computerized literature search was conducted in PubMed. A total of 12 and 6 studies meeting the inclusion criteria were, respectively, included in meta-analysis about dose-adjusted trough concentration (C0/D) and dose-adjusted peak concentration (C2/D). The combined weighted mean difference (WMD) between CYP3A5 expressers (*1/*3 + *1/*1) and non-expressers (*3/*3) was significant in C2/D (WMD=−12.73 (ng ml–1)/(mg kg–1), 95% confidence interval (CI) −25.23 to −0.22, P=0.046), whereas it was marginally significant in C0/D (WMD=−3.75 (ng ml–1)/(mg kg–1), 95% CI −7.58 to 0.07, P=0.054). Exclusion of an outlier study greatly increased the association of CYP3A5 polymorphism with C0/D to be significant (WMD=−4.92 (ng ml–1)/(mg kg–1), 95% CI: −8.27 to −1.58, P=0.011). This meta-analysis showed that CYP3A5*3 polymorphism is associated with CsA dose-adjusted concentration in renal transplant recipients. Patients carrying the CYP3A5*3/*3 genotype will require a lower dose of CsA to reach target levels compared with the CYP3A5*1/*1 or *1/*3 carriers.

This publication has 32 references indexed in Scilit: